Business, energy, technology, markets and global industry news from Business News Today

IL-23 inhibitor

PharmaDeviceNews IL-23 inhibitor
Representative image showing a clinician reviewing joint health with a patient, reflecting Johnson & Johnson’s Tremfya FDA label expansion for structural joint damage inhibition in active psoriatic arthritis.
Pharma & Biotech

Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?

Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.

Read More
AbbVie Phase 3 AFFIRM data what subcutaneous risankizumab induction could change in Crohn’s disease treatment
Pharma & Biotech

AbbVie’s AFFIRM trial: what clinicians should watch next for risankizumab in Crohn’s disease

AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.

Read More